FIT Biotech Oy
Press Release July 3 rd 2018, 10.00 EET
FIT Biotech webcasts the company half-year financial report on September 6 th 2018, at 10.00 AM.
FIT Biotech's half-year financial report will be webcasted on September 6 th 2018, at 10.00 AM.
The webcast can be followed in the following link: https://www.inderes.fi/videot/fit-biotech-web...000-alkaen
Additional information: CEO Erkki Pekkarinen Phone +358 44 027 0080 email: erkki.pekkarinen@fitbiotech.com
About FIT Biotech FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
DISTRIBUTION: Principal media www.fitbiotech.fi